Ivabradine and AF: Coincidence, Correlation or a New Treatment?
Ivabradine and AF: Coincidence, Correlation or a New Treatment?
复制标题
伊伐布雷定和房颤：巧合、相关还是新的治疗方法？
DOI：
--
复制
发表时间：
2019
影响因子：
3
通讯作者：
H. Badran
中科院分区：
文献类型：
--
作者：
M. Abdelnabi;Ashraf Ahmed;A. Almaghraby;Y. Saleh;H. Badran
伊伐布雷定是一种降低心率的药物，可抑制起搏器有趣电流（If）。它已被欧洲药品管理局和美国食品和药物管理局批准用于稳定型心绞痛和心力衰竭（HF）患者。AF是一种常见问题，尤其是在缺血性心脏病和HF患者中。与证明伊伐布雷定在AF中控制心率或维持窦性心律的新兴作用的实验结果和有限数量的临床试验相反，累积的矛盾数据表明，实际上，在临床实践中服用伊伐布雷定的人群中新发AF的发生率增加。这篇文章回顾了最新证据，强调了伊伐布雷定使用和AF发作相关数据的多样性，以及伊伐布雷定在AF治疗和维持窦性心律中是否具有合理作用。
Ivabradine is a heart rate-lowering agent that inhibits pacemaker funny current (If). It has been approved by the European Medicines Agency and the US Food and Drug Administration for patients with stable angina and heart failure (HF). AF is a common issue especially in ischaemic heart disease and HF patients. In contrast to experimental findings and a limited number of clinical trials that demonstrate the emerging role of ivabradine for heart rate control in AF or maintenance of sinus rhythm, there is accumulating contradictory data indicating that there is, in fact, an increased incidence of new-onset AF among people who are taking ivabradine in clinical practice. This article reviews the most recent evidence highlighting the diversity of data in relation to the use of ivabradine and the onset of AF and whether it has a legitimate role in AF treatment and the maintenance of sinus rhythm.